We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -0.25% | 28.08 | 28.025 | 28.08 | 28.35 | 27.945 | 28.185 | 191,455 | 20:59:49 |
By Joshua Kirby
Bayer AG said Thursday that it has reached an agreement to sell a testosterone-deficiency treatment to pharmaceutical company Gruenenthal for up to 500 million euros ($503 million).
The treatment, Nebido, is for male hypogonadism and is available in over 80 countries, the German conglomerate said. Last year, Nebido contributed sales of EUR117 million to group revenue, Bayer said.
The transaction should be completed by the end of the year, subject to approvals, the company said.
"This divestment is part of the ongoing transformation of our pharmaceuticals business, which focuses on key areas of healthcare innovation," Marianne De Backer, head of strategy and business development at Bayer's pharmaceuticals division, said. "Its proceeds will support investments in future innovation and bring forward transformative treatment options for patients," she said.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
July 14, 2022 02:32 ET (06:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions